FDA approves first new sunscreen ingredient in more than 20 years

The recent approval of bemotrizinol by the U.S. Food and Drug Administration (FDA) represents a significant shift in the landscape of sunscreen regulation and consumer choice. For over two decades, the U.S. has lagged behind other nations in introducing new sunscreen ingredients, despite growing concerns about the safety and effectiveness of existing products. Bemotrizinol, a chemical long used in Europe, Australia, and parts of Asia, is now available in the United States, marking the first new sunscreen ingredient approved by the FDA since 1999. This development has sparked widespread interest among consumers, healthcare professionals, and advocacy groups who have long criticized the slow pace of regulatory updates in the U.S. Compared to other regions, where sunscreen technology has advanced significantly, American consumers have relied on outdated formulations that may pose health risks.

The journey of bemotrizinol to FDA approval highlights the challenges of navigating the U.S. regulatory framework. Unlike in the European Union, where sunscreen ingredients are classified as cosmetics and subject to less stringent oversight, the FDA treats them as over-the-counter drugs, requiring extensive safety testing and documentation. This classification has historically slowed the introduction of new ingredients, as companies must navigate complex and time-consuming approval processes. Bemotrizinol was first authorized in Europe in 1999 and became available in the U.S. only after a prolonged effort involving multiple rounds of research, regulatory submissions, and lobbying by the manufacturer, DSM Nutritional Products. The approval process was further complicated by the lack of a streamlined pathway for evaluating new sunscreen ingredients, a situation that changed in 2020 with the passage of provisions in the CARES Act aimed at expediting approvals.

The implications of this approval extend beyond mere convenience for consumers. Bemotrizinol is marketed as a safer and more effective alternative to traditional chemical sunscreens, which have raised concerns about hormone disruption and potential carcinogenic effects. Studies have suggested that certain chemical sunscreens can absorb into the bloodstream, raising questions about long-term health impacts. In contrast, bemotrizinol is described as having minimal skin absorption and offering broad-spectrum protection against both UVA and UVB rays. This dual protection is particularly valuable, as UVA rays contribute to premature aging and skin damage, while UVB rays are primarily responsible for sunburn and skin cancer. Moreover, bemotrizinol is noted for its stability under sunlight, meaning it maintains its protective properties for longer periods without degrading, unlike many current chemical sunscreens that require frequent reapplication.

The approval of bemotrizinol also reflects broader shifts in public health priorities and regulatory reform efforts. Advocacy groups, such as the Environmental Working Group, have long campaigned for stricter sunscreen regulations and greater transparency in product labeling. Their efforts have contributed to increased scrutiny of existing sunscreen formulations and pressure on the FDA to update its standards. The inclusion of bemotrizinol in the U.S. market aligns with these goals, offering consumers a potentially safer and more effective option. Additionally, the approval underscores the influence of political figures and organizations advocating for regulatory reform. For instance, Health and Human Services Secretary Robert F. Kennedy Jr. has championed the Make America Healthy Again movement, emphasizing the importance of aligning U.S. regulations with global best practices. This sentiment resonates with a growing public demand for more rigorous oversight of personal care products, especially in light of increasing awareness of environmental and health risks associated with synthetic chemicals.

Despite the positive developments, challenges remain. The initial availability of bemotrizinol is limited to the Dutch manufacturer DSM, which holds an 18-month exclusivity period before allowing other producers to enter the market. This restriction means that consumers may face limited choices and higher prices during the early stages of adoption. Furthermore, while bemotrizinol is presented as a superior alternative to chemical sunscreens, it is not without its drawbacks. Some users may experience difficulty applying it evenly, particularly on darker skin tones, as it can leave a slight white residue. To address this, several brands have begun developing tinted versions of mineral-based sunscreens that blend more naturally with skin tones, offering a compromise between effectiveness and aesthetics.

As the U.S. market begins to incorporate bemotrizinol, the focus will shift toward educating consumers about proper usage and the benefits of newer, more scientifically validated formulations. Public health campaigns will play a crucial role in promoting consistent sunscreen application, as even the most advanced products are ineffective if not used correctly. The FDA has emphasized the importance of applying sunscreen 15 minutes before sun exposure and reapplying every two hours, especially after swimming or sweating. These guidelines underscore the necessity of user education alongside product innovation.

Looking ahead, the approval of bemotrizinol is expected to catalyze further changes in the sunscreen industry. With the FDA now open to considering new ingredients through streamlined pathways, there is potential for more rapid advancements in the field. Advocacy groups continue to push for broader regulatory reforms, including the adoption of international drug reciprocity policies that would allow the U.S. to approve foreign-safe ingredients more quickly. Meanwhile, consumers are increasingly seeking out mineral-based alternatives, which provide physical barriers against UV radiation without the potential systemic absorption of chemical sunscreens. As the market evolves, the balance between innovation, safety, and accessibility will remain central to shaping the future of sunscreen use in the United States.